Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis assess clinical evidence for digital health applications targeting metabolic disorders, indicating modest benefits in Germany.
UNSTRUCTURED In Germany, digital health applications (DiGAs) can be prescribed and reimbursed after regulatory approval. This systematic review and meta-analysis evaluated the clinical evidence for reimbursed DiGAs targeting metabolic disorders, including diabetes and obesity. We systematically searched the German DiGA directory, manufacturer websites and relevant study registers up to May 2025. Eligible studies were German-based studies assessing at least one of two primary outcomes: HbA1c or body weight. 17 studies reporting evidence for eight DiGAs met inclusion criteria. The Meta-analysis for the group difference in HbA1c reduction showed a modest but significant benefit for DiGA users (mean difference: –0.34%). Results for weight and especially further secondary outcomes like self-management and well-being were more heterogeneous. Most studies showed moderate risk of bias. While current evidence indicates small but relevant benefits, traditional trial designs may only partially capture the value of DiGA, suggesting a need for adapted evaluation approaches.
No takes yet. Share an insight, caveat, or question.
Roth et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: